<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<meta http-equiv="Content-Security-Policy" content="upgrade-insecure-requests">
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>GLP-1 Patent SavaÅŸlarÄ± ve Yeni Nesil Ä°laÃ§lar: 2026'da Neler DeÄŸiÅŸiyor? | UzunYaÅŸa</title>
<meta name="description" content="2026'da GLP-1 ilaÃ§larÄ±nda patent sÃ¼releri doluyor, yeni nesil Ã¼Ã§lÃ¼ agonistler ve oral tedaviler geliyor. Semaglutid patent savaÅŸlarÄ±, retatrutid, orforglipron ve obezite tedavisinin geleceÄŸi.">
<meta name="author" content="UzunYaÅŸa">
<link rel="canonical" href="https://uzunyasa.com/pages/blog/glp1-patent-savaÅŸlarÄ±-2026-yeni-nesil-ilaÃ§lar.html">
<!-- Open Graph -->
<meta property="og:title" content="GLP-1 Patent SavaÅŸlarÄ± ve Yeni Nesil Ä°laÃ§lar: 2026'da Neler DeÄŸiÅŸiyor? | UzunYaÅŸa">
<meta property="og:description" content="2026'da GLP-1 ilaÃ§larÄ±nda patent sÃ¼releri doluyor, yeni nesil Ã¼Ã§lÃ¼ agonistler ve oral tedaviler geliyor. Obezite tedavisinin geleceÄŸi.">
<meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
<meta property="og:url" content="https://uzunyasa.com/pages/blog/glp1-patent-savaÅŸlarÄ±-2026-yeni-nesil-ilaÃ§lar.html">
<meta property="og:type" content="article">
<meta property="og:locale" content="tr_TR">
<meta property="article:published_time" content="2026-02-10">
<!-- Fonts -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&family=Playfair+Display:wght@400;500;600;700&display=swap" rel="stylesheet">
<!-- Styles -->
<link rel="stylesheet" href="../../styles/main.css">
<link rel="stylesheet" href="../../styles/content-page.css">
<link rel="stylesheet" href="../../styles/animations.css">
<style>
/* ===== READING PROGRESS BAR ===== */
.blog-progress {
  position: fixed; top: 0; left: 0; width: 0%;
  height: 3px; z-index: 10001;
  background: linear-gradient(90deg, #0D7377, #14919B, #E8963E);
  transition: width 0.1s linear;
}

/* ===== BLOG HERO ===== */
.blog-hero {
  position: relative;
  min-height: 480px;
  display: flex;
  align-items: flex-end;
  overflow: hidden;
  margin-top: 70px;
}
.blog-hero-img {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  object-fit: cover;
}
.blog-hero-overlay {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  background: linear-gradient(180deg,
    rgba(25,81,87,0.3) 0%,
    rgba(25,81,87,0.55) 40%,
    rgba(15,61,66,0.88) 100%);
}
.blog-hero-content {
  position: relative; z-index: 2;
  max-width: 860px; margin: 0 auto;
  padding: 3rem 2rem 3.5rem;
  color: white;
}
.blog-hero-badge {
  display: inline-block;
  padding: 0.4rem 1rem;
  border-radius: 20px;
  font-size: 0.8rem; font-weight: 600;
  margin-bottom: 1.25rem;
  background: #E8963E;
  color: white;
}
.blog-hero-title {
  font-family: 'Playfair Display', serif;
  font-size: clamp(2rem, 4vw, 2.8rem);
  font-weight: 600;
  line-height: 1.2;
  margin-bottom: 1rem;
  text-shadow: 0 2px 8px rgba(0,0,0,0.3);
}
.blog-hero-subtitle {
  font-size: 1.15rem;
  opacity: 0.9;
  max-width: 640px;
  line-height: 1.7;
  margin-bottom: 1.25rem;
}
.blog-hero-meta {
  display: flex; gap: 1.5rem; flex-wrap: wrap;
  font-size: 0.85rem; opacity: 0.8;
}
.blog-hero-meta span { display: flex; align-items: center; gap: 0.4rem; }

/* ===== ARTICLE BODY ===== */
.blog-article {
  max-width: 800px;
  margin: 0 auto;
  padding: 2.5rem 2rem 4rem;
}

/* ===== BREADCRUMB ===== */
.blog-breadcrumb {
  display: flex; align-items: center; gap: 0.5rem;
  font-size: 0.85rem; color: var(--text-light);
  margin-bottom: 2rem; flex-wrap: wrap;
}
.blog-breadcrumb a {
  color: var(--primary); text-decoration: none; font-weight: 500;
}
.blog-breadcrumb a:hover { text-decoration: underline; }

/* ===== TOC ===== */
.blog-toc {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border: 1px solid #e2e8f0;
  border-left: 4px solid var(--primary);
  border-radius: 0 16px 16px 0;
  padding: 1.75rem 2rem;
  margin-bottom: 2.5rem;
}
.blog-toc h4 {
  font-size: 0.9rem; font-weight: 700;
  text-transform: uppercase; letter-spacing: 0.06em;
  color: var(--primary); margin-bottom: 1rem;
}
.blog-toc ol {
  list-style: none; counter-reset: toc; margin: 0; padding: 0;
}
.blog-toc li { counter-increment: toc; margin-bottom: 0.4rem; }
.blog-toc li a {
  display: flex; align-items: center; gap: 0.6rem;
  text-decoration: none; color: #334155;
  font-size: 0.95rem; padding: 0.4rem 0.6rem;
  border-radius: 8px; transition: all 0.2s;
}
.blog-toc li a::before {
  content: counter(toc);
  display: inline-flex; align-items: center; justify-content: center;
  width: 26px; height: 26px;
  background: #e2e8f0; border-radius: 50%;
  font-size: 0.75rem; font-weight: 700; color: #475569;
  flex-shrink: 0; transition: all 0.2s;
}
.blog-toc li a:hover { background: rgba(13,115,119,0.08); color: var(--primary); }
.blog-toc li a:hover::before { background: var(--primary); color: white; }

/* ===== CONTENT STYLES ===== */
.blog-content p {
  font-size: 1.05rem; line-height: 1.8; margin-bottom: 1.5rem; color: var(--text-dark);
}
.blog-content h2 {
  font-size: 1.5rem; font-weight: 700; color: var(--primary);
  margin: 3rem 0 1.25rem; padding-top: 2rem;
  border-top: 1px solid var(--border);
  position: relative; padding-bottom: 0.75rem;
}
.blog-content h2::after {
  content: ''; position: absolute; bottom: 0; left: 0;
  width: 60px; height: 3px;
  background: linear-gradient(90deg, var(--primary), #10b981);
  border-radius: 2px;
}
.blog-content h2:first-of-type { border-top: none; padding-top: 0; margin-top: 0; }
.blog-content h3 {
  font-size: 1.2rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text-dark);
}
.blog-content ul, .blog-content ol {
  margin: 1.25rem 0; padding-left: 1.5rem;
}
.blog-content li { margin-bottom: 0.5rem; font-size: 1.02rem; line-height: 1.7; }
.blog-content strong { color: var(--text-dark); }
.blog-content a { color: var(--primary); text-decoration: underline; }

/* ===== INFO BOXES ===== */
.blog-box {
  padding: 1.5rem 1.75rem;
  border-radius: 0 14px 14px 0;
  margin: 2rem 0;
  border-left: 4px solid;
  position: relative;
  display: flex; gap: 1rem; align-items: flex-start;
}
.blog-box .box-icon {
  flex-shrink: 0; width: 28px; height: 28px; margin-top: 2px;
}
.blog-box .box-body { flex: 1; }
.blog-box .box-body strong { display: block; margin-bottom: 0.4rem; font-size: 0.95rem; }
.blog-box .box-body p, .blog-box .box-body ul { margin: 0; font-size: 0.95rem; line-height: 1.7; }
.blog-box .box-body ul { padding-left: 1.2rem; margin-top: 0.5rem; }
.blog-box .box-body li { margin-bottom: 0.3rem; }

.blog-box.info {
  background: linear-gradient(135deg, #eff6ff, #f0f9ff);
  border-left-color: #3B82F6;
}
.blog-box.info .box-icon { color: #3B82F6; }
.blog-box.warning {
  background: linear-gradient(135deg, #fef3c7, #fffbeb);
  border-left-color: #F59E0B;
}
.blog-box.warning .box-icon { color: #F59E0B; }
.blog-box.success {
  background: linear-gradient(135deg, #ecfdf5, #f0fdf4);
  border-left-color: #10B981;
}
.blog-box.success .box-icon { color: #10B981; }
.blog-box.danger {
  background: linear-gradient(135deg, #fef2f2, #fee2e2);
  border-left-color: #EF4444;
}
.blog-box.danger .box-icon { color: #EF4444; }
.blog-box.tip {
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
  border-left-color: #0D7377;
}
.blog-box.tip .box-icon { color: #0D7377; }

/* ===== KEY STAT BOX ===== */
.key-stat {
  display: flex; align-items: center; gap: 1.5rem;
  padding: 1.75rem 2rem;
  border-radius: 0 16px 16px 0;
  margin: 2rem 0;
  border-left: 5px solid var(--primary);
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
}
.key-stat .ks-num {
  font-size: 2.75rem; font-weight: 800; color: var(--primary);
  line-height: 1; white-space: nowrap;
}
.key-stat .ks-text { font-size: 0.95rem; color: #195157; line-height: 1.6; }
.key-stat.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
.key-stat.accent .ks-num { color: #E8963E; }
.key-stat.danger { border-left-color: #EF4444; background: linear-gradient(135deg, #fef2f2, #fee2e2); }
.key-stat.danger .ks-num { color: #EF4444; }

/* ===== STAT CARDS ===== */
.stat-cards {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
  gap: 1rem; margin: 2rem 0;
}
.stat-card {
  background: white;
  border: 1px solid var(--border);
  border-radius: 16px;
  padding: 1.5rem;
  text-align: center;
  transition: all 0.3s ease;
  position: relative; overflow: hidden;
}
.stat-card::before {
  content: ''; position: absolute; top: 0; left: 0; right: 0;
  height: 3px;
  background: linear-gradient(90deg, var(--primary), var(--accent));
}
.stat-card:hover { transform: translateY(-4px); box-shadow: 0 12px 30px rgba(0,0,0,0.1); }
.stat-card .sc-num {
  font-size: 2rem; font-weight: 800; color: var(--primary);
  margin-bottom: 0.25rem;
}
.stat-card .sc-label {
  font-size: 0.8rem; color: var(--text-light); line-height: 1.4;
}

/* ===== COMPARISON TABLE ===== */
.blog-table {
  width: 100%; border-collapse: collapse; margin: 2rem 0;
  font-size: 0.95rem; border-radius: 12px; overflow: hidden;
  border: 1px solid var(--border);
}
.blog-table th {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  padding: 1rem; text-align: left; font-weight: 600;
  color: var(--primary); border-bottom: 2px solid var(--primary);
}
.blog-table td {
  padding: 0.85rem 1rem; border-bottom: 1px solid var(--border);
}
.blog-table tr:hover td { background: rgba(13,115,119,0.03); }
.blog-table tr:last-child td { border-bottom: none; }

/* ===== SVG INFOGRAPHIC ===== */
.blog-infographic {
  margin: 2.5rem 0; padding: 2rem;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border: 1px solid #e2e8f0;
  text-align: center;
}
.blog-infographic svg { max-width: 100%; height: auto; }
.blog-infographic figcaption {
  margin-top: 1rem; font-size: 0.85rem;
  color: var(--text-light); font-style: italic;
}

/* ===== PULL QUOTE ===== */
.blog-quote {
  position: relative;
  padding: 2rem 2.5rem;
  margin: 2.5rem 0;
  font-size: 1.15rem; font-style: italic;
  color: #334155; line-height: 1.7;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border-left: 4px solid var(--primary);
}
.blog-quote::before {
  content: '\201C'; position: absolute; top: -8px; left: 16px;
  font-size: 4rem; color: rgba(13,115,119,0.12);
  font-family: Georgia, serif; line-height: 1;
}
.blog-quote cite {
  display: block; margin-top: 0.75rem;
  font-size: 0.9rem; font-style: normal;
  font-weight: 600; color: var(--primary);
}

/* ===== KEY TAKEAWAY ===== */
.blog-takeaway {
  background: linear-gradient(135deg, #195157, #2a6b73);
  color: white; padding: 2rem; border-radius: 16px;
  margin: 2.5rem 0; position: relative; overflow: hidden;
}
.blog-takeaway::before {
  content: ''; position: absolute; top: -30%; right: -10%;
  width: 200px; height: 200px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-takeaway h4 {
  font-size: 0.85rem; text-transform: uppercase;
  letter-spacing: 0.1em; opacity: 0.8; margin-bottom: 0.75rem;
}
.blog-takeaway ul { list-style: none; padding: 0; margin: 0; }
.blog-takeaway li {
  padding: 0.5rem 0 0.5rem 1.75rem; position: relative;
  font-size: 0.95rem; line-height: 1.6;
}
.blog-takeaway li::before {
  content: '\2713'; position: absolute; left: 0;
  color: #10b981; font-weight: 700;
}

/* ===== BAR CHART ===== */
.bar-chart { margin: 2.5rem 0; }
.bar-chart h4 { font-size: 1rem; font-weight: 700; color: var(--primary); margin-bottom: 1.25rem; }
.bar-row { display: flex; align-items: center; gap: 1rem; margin-bottom: 0.75rem; }
.bar-label { width: 120px; font-size: 0.85rem; font-weight: 600; color: var(--text-dark); flex-shrink: 0; }
.bar-track { flex: 1; height: 32px; background: #eef3f4; border-radius: 8px; overflow: hidden; }
.bar-fill {
  height: 100%; border-radius: 8px;
  display: flex; align-items: center; justify-content: flex-end;
  padding-right: 10px; font-size: 0.8rem; font-weight: 700; color: white;
  transform-origin: left; transform: scaleX(0);
  transition: transform 1s cubic-bezier(0.4,0,0.2,1);
}
.bar-fill.anim-visible { transform: scaleX(1); }
.bar-fill.clr-primary { background: linear-gradient(90deg, #0D7377, #14919B); }
.bar-fill.clr-accent { background: linear-gradient(90deg, #E8963E, #F5B06B); }
.bar-fill.clr-dark { background: linear-gradient(90deg, #195157, #2a7a82); }
.bar-fill.clr-success { background: linear-gradient(90deg, #059669, #10B981); }

/* ===== CTA BOX ===== */
.blog-cta {
  background: linear-gradient(135deg, var(--primary), #2a7d83);
  color: white; padding: 2.5rem; border-radius: 20px;
  text-align: center; margin: 3rem 0;
  position: relative; overflow: hidden;
}
.blog-cta::before {
  content: ''; position: absolute; top: -50%; right: -30%;
  width: 300px; height: 300px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-cta h3 { font-size: 1.5rem; font-weight: 700; margin-bottom: 0.75rem; }
.blog-cta p { opacity: 0.9; margin-bottom: 1.5rem; max-width: 400px; margin-left: auto; margin-right: auto; }
.blog-cta a {
  display: inline-block;
  background: white; color: var(--primary);
  padding: 0.875rem 2rem; border-radius: 10px;
  text-decoration: none; font-weight: 700; font-size: 1rem;
  transition: all 0.3s;
}
.blog-cta a:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 25px rgba(0,0,0,0.2);
}

/* ===== AUTHOR BOX ===== */
.blog-author {
  display: flex; align-items: center; gap: 1.25rem;
  padding: 1.75rem; background: white;
  border-radius: 16px; border: 1px solid var(--border);
  margin: 2.5rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.04);
}
.blog-author-avatar {
  width: 64px; height: 64px; border-radius: 50%;
  background: linear-gradient(135deg, var(--primary), var(--primary-light));
  display: flex; align-items: center; justify-content: center;
  color: white; font-weight: 700; font-size: 1.1rem;
  flex-shrink: 0;
}
.blog-author-info h4 { font-weight: 600; margin-bottom: 0.25rem; font-size: 1rem; }
.blog-author-info p { font-size: 0.85rem; color: var(--text-light); margin: 0; line-height: 1.5; }

/* ===== RELATED POSTS ===== */
.blog-related { margin: 3rem 0; }
.blog-related h3 {
  font-size: 1.25rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 1.5rem;
}
.related-grid {
  display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
  gap: 1.25rem;
}
.related-card {
  background: white; border: 1px solid var(--border);
  border-radius: 14px; overflow: hidden;
  text-decoration: none; color: inherit;
  transition: all 0.3s ease;
}
.related-card:hover {
  transform: translateY(-4px);
  box-shadow: 0 12px 30px rgba(0,0,0,0.1);
  border-color: var(--primary);
}
.related-card-img {
  height: 140px; background-size: cover; background-position: center;
  position: relative;
}
.related-card-img::after {
  content: ''; position: absolute; bottom: 0; left: 0; right: 0;
  height: 50%;
  background: linear-gradient(to top, rgba(0,0,0,0.4), transparent);
}
.related-card-body { padding: 1rem 1.25rem; }
.related-card-body h4 {
  font-size: 0.95rem; font-weight: 600; line-height: 1.4;
  margin-bottom: 0.5rem; color: var(--text-dark);
}
.related-card-body p {
  font-size: 0.8rem; color: var(--text-light); margin: 0;
}

/* ===== SOCIAL SHARING ===== */
.blog-share {
  display: flex; align-items: center; gap: 0.75rem;
  margin: 2rem 0; padding: 1.25rem 0;
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
}
.blog-share span { font-size: 0.9rem; font-weight: 600; color: var(--text-medium); }
.share-btn {
  display: inline-flex; align-items: center; justify-content: center;
  width: 40px; height: 40px; border-radius: 50%;
  border: 1px solid var(--border); background: white;
  color: var(--text-medium); text-decoration: none;
  transition: all 0.2s; cursor: pointer;
}
.share-btn:hover { border-color: var(--primary); color: var(--primary); background: rgba(13,115,119,0.05); }
.share-btn svg { width: 18px; height: 18px; }

/* ===== NEWSLETTER ===== */
.blog-newsletter {
  background: linear-gradient(135deg, var(--bg-cream), #f0f9ff);
  border: 2px solid var(--border);
  border-radius: 20px;
  padding: 2.5rem;
  text-align: center;
  margin: 3rem 0;
}
.blog-newsletter h3 {
  font-size: 1.3rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 0.5rem;
}
.blog-newsletter p {
  color: var(--text-medium); margin-bottom: 1.5rem; font-size: 0.95rem;
}
.newsletter-form {
  display: flex; max-width: 420px; margin: 0 auto; gap: 0.5rem;
}
.newsletter-form input {
  flex: 1; padding: 0.875rem 1rem;
  border: 1px solid var(--border); border-radius: 10px;
  font-size: 0.95rem; font-family: inherit;
}
.newsletter-form input:focus {
  outline: none; border-color: var(--primary);
  box-shadow: 0 0 0 3px rgba(13,115,119,0.1);
}
.newsletter-form button {
  background: var(--primary); color: white;
  padding: 0.875rem 1.5rem; border: none; border-radius: 10px;
  font-weight: 600; font-size: 0.95rem; cursor: pointer;
  transition: all 0.2s; font-family: inherit;
}
.newsletter-form button:hover {
  background: var(--primary-dark);
  transform: translateY(-1px);
}

/* ===== DISCLAIMER ===== */
.blog-disclaimer {
  font-size: 0.8rem; color: var(--text-light);
  margin-top: 2rem; padding-top: 1.5rem;
  border-top: 1px solid var(--border);
  line-height: 1.6;
}

/* ===== RESPONSIVE ===== */
@media (max-width: 768px) {
  .blog-hero { min-height: 380px; }
  .blog-hero-title { font-size: 1.8rem; }
  .blog-hero-content { padding: 2rem 1.5rem 2.5rem; }
  .blog-article { padding: 2rem 1.25rem 3rem; }
  .key-stat { flex-direction: column; text-align: center; padding: 1.5rem; }
  .key-stat .ks-num { font-size: 2rem; }
  .blog-author { flex-direction: column; text-align: center; }
  .stat-cards { grid-template-columns: repeat(2, 1fr); }
  .bar-label { width: 80px; font-size: 0.8rem; }
  .newsletter-form { flex-direction: column; }
  .related-grid { grid-template-columns: 1fr; }
  .blog-share { flex-wrap: wrap; }
}
</style>
</head>
<body>

<!-- Reading Progress Bar -->
<div class="blog-progress" id="blogProgress"></div>

<!-- HEADER -->
<header class="header">
  <div class="header-inner">
    <a href="../../index.html" class="logo">
      <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="logo-img">
    </a>
    <nav class="nav">
      <ul class="nav-links">
        <li class="nav-dropdown">
          <a href="#" class="nav-link">Kesfet</a>
          <div class="nav-dropdown-content">
            <a href="../beslenme.html" class="nav-dropdown-item">Beslenme</a>
            <a href="../egzersiz.html" class="nav-dropdown-item">Egzersiz</a>
            <a href="../tedavi.html" class="nav-dropdown-item">Kilo Yonetimi</a>
            <a href="../uyku-stres.html" class="nav-dropdown-item">Zihin & Davranis</a>
          </div>
        </li>
        <li><a href="../blog.html" class="nav-link aÃ§tÄ±ve">Blog</a></li>
        <li><a href="../araclar.html" class="nav-link">Araclar</a></li>
        <li><a href="../hikayeler.html" class="nav-link">Hikayeler</a></li>
        <li><a href="../bilim.html" class="nav-link">Bilim</a></li>
        <li><a href="../hakkimizda.html" class="nav-link">Hakkimizda</a></li>
      </ul>
      <a href="../test.html" class="btn btn-primary">Teste BaÅŸla</a>
    </nav>
  </div>
</header>

<!-- HERO -->
<section class="blog-hero">
  <img class="blog-hero-img" src="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&q=80" alt="GLP-1 Patent SavaÅŸlarÄ± 2026">
  <div class="blog-hero-overlay"></div>
  <div class="blog-hero-content anim-slide-up anim-visible">
    <span class="blog-hero-badge">Tedavi</span>
    <h1 class="blog-hero-title">GLP-1 Patent SavaÅŸlarÄ± ve Yeni Nesil Ä°laÃ§lar: 2026'da Neler DeÄŸiÅŸiyor?</h1>
    <p class="blog-hero-subtitle">Semaglutid patentleri doluyor, dev ÅŸirketler mahkemede, yeni nesil Ã¼Ã§lÃ¼ agonistler kapÄ±da. Obezite tedavisinin gelecegi burada.</p>
    <div class="blog-hero-meta">
      <span>10 Subat 2026</span>
      <span>12 dk okuma</span>
      <span>UzunYasa EditÃ¶ryal</span>
    </div>
  </div>
</section>

<!-- ARTICLE -->
<article class="blog-article">

  <!-- Breadcrumb -->
  <nav class="blog-breadcrumb" aria-label="Breadcrumb">
    <a href="../../index.html">Ana Sayfa</a>
    <span>&rsaquo;</span>
    <a href="../blog.html">Blog</a>
    <span>&rsaquo;</span>
    <span>GLP-1 Patent SavaÅŸlarÄ± 2026</span>
  </nav>

  <!-- Table of Contents -->
  <div class="blog-toc anim-slide-up">
    <h4>Ä°Ã§indekiler</h4>
    <ol>
      <li><a href="#bolum-1">BÃ¼yÃ¼k Resim: GLP-1 Pazari 2026'da Nerede?</a></li>
      <li><a href="#bolum-2">Patent SavaÅŸlarÄ±: Novo Nordisk vs. Kopya Ãœretim</a></li>
      <li><a href="#bolum-3">FDA'nin Kopya GLP-1'lere Karsi Tutumu</a></li>
      <li><a href="#bolum-4">Yeni Nesil Ä°laÃ§lar: ÃœÃ§lÃ¼ Agonistler ve Oral Tedaviler</a></li>
      <li><a href="#bolum-5">KarÅŸÄ±laÅŸtÄ±rma: Mevcut ve Gelecek GLP-1 Tedavileri</a></li>
      <li><a href="#bolum-6">TÃ¼rkiye Ä°Ã§in Ne Anlama Geliyor?</a></li>
      <li><a href="#bolum-7">Sonuc ve Ana Ã‡Ä±karÄ±mlar</a></li>
    </ol>
  </div>

  <!-- Content -->
  <div class="blog-content">

    <h2 id="bolum-1">BÃ¼yÃ¼k Resim: GLP-1 Pazari 2026'da Nerede?</h2>

    <p>Obezite tedavisinde yaygÄ±nlaÅŸan GLP-1 reseptÃ¶r agonistleri, 2026 yÄ±lÄ±nda Ã¶nemli bir dÃ¶nemeÃ§e giriyor. Bir yanda patent sÃ¼releri dolmaya baÅŸlayan semaglutid, diÄŸer yanda 100'den fazla yeni molekÃ¼l geliÅŸtirme aÅŸamasÄ±nda.</p>

    <div class="key-stat accent anim-slide-up">
      <span class="ks-num">~$67 Milyar</span>
      <span class="ks-text">GLP-1 obezite ilaÃ§ pazarÄ±nÄ±n 2035 yÄ±lÄ±na kadar ulaÅŸmasÄ± beklenen bÃ¼yÃ¼klÃ¼k (Precedence Research tahmini). 2025'te bu rakam yaklaÅŸÄ±k $25 milyar seviyesindeydi.</span>
    </div>

    <p>ABD'de GLP-1 reÃ§etelerinde 2019-2024 arasinda <strong>%500'den fazla artis</strong> yaÅŸandi. Wegovy, Ozempic, Mounjaro gibi isimler artik sadece tip dunyasinin degil, gunluk konusmalarin da parÃ§asi. Ancak bu bÃ¼yÃ¼k buyumenin arkasinda dev bir patent savaÅŸÄ± ve regÃ¼lasyon krizi gizleniyor.</p>

    <div class="stat-cards anim-slide-up">
      <div class="stat-card"><div class="sc-num">%500+</div><div class="sc-label">ABD'de GLP-1 reÃ§ete artÄ±ÅŸÄ± (2019-2024)</div></div>
      <div class="stat-card"><div class="sc-num">1.5M</div><div class="sc-label">ABD'de kopya GLP-1 kullanan hasta sayisi</div></div>
      <div class="stat-card"><div class="sc-num">100+</div><div class="sc-label">GeliÅŸtirme aÅŸamasÄ±ndaki yeni molekÃ¼l</div></div>
      <div class="stat-card"><div class="sc-num">35+</div><div class="sc-label">GLP-1 bazli pipeline bileÅŸigi</div></div>
    </div>

    <h2 id="bolum-2">Patent SavaÅŸlarÄ±: Novo Nordisk vs. Kopya Ãœretim</h2>

    <p>9 Subat 2026'da patlak veren gelisme, obezite ilaÃ§ pazarindaki gerilimi zirveye tasidi: <strong>Novo Nordisk, Hims &amp; Hers'e dava aÃ§tÄ±.</strong> Danimarkali ilaÃ§ devi, ABD'nin en bÃ¼yÃ¼k online saÄŸlÄ±k platformunun Wegovy hapinin ve enjeksiyonlarinin onaysiz kopyalarini kitlesel olarak sattigini iddia ediyor.</p>

    <div class="blog-box danger anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="15" y1="9" x2="9" y2="15"/><line x1="9" y1="9" x2="15" y2="15"/></svg>
      <div class="box-body">
        <strong>Dava Detaylari (9 Subat 2026)</strong>
        <ul>
          <li>Novo Nordisk, Hims'in kopya Ã¼rÃ¼nlerinin kalici olarak yasaklanmasini talep ediyor</li>
          <li>Semaglutid ABD patentleri 2032'ye kadar koruma altinda</li>
          <li>Hims hisselerinde tek gunde <strong>%18 dÃ¼ÅŸÃ¼ÅŸ</strong> yaÅŸandi</li>
          <li>Hims, kopya Wegovy hapini aylik 49$'a sunmayi planlamisti &mdash; orijinalden ~100$ ucuz</li>
        </ul>
      </div>
    </div>

    <p>Novo Nordisk Hukuk Genel MÃ¼dÃ¼rÃ¼ John Kuckelman durumu net bir dille ortaya koydu: <em>"Bu tamamen bir aldatmaca ve ilaÃ§ kÄ±tlÄ±ÄŸi sona erdiginden beri oyle. Onlarin ilaÃ§lari test edilmemis ve hastalari riske atÄ±yor."</em></p>

    <blockquote class="blog-quote anim-slide-up">
      Kopya ilaÃ§ Ã¼retimi, bir doktorun hasta iÃ§in tÄ±bbi olarak gerekli gordugu durumlarda &mdash; Ã¶rneÄŸi hapÄ± yutamayan veya belirli bir maddeye alerjik olan hastalar iÃ§in &mdash; vaka bazinda yapilabilir. Ancak "kiÅŸisellestirilmis ilaÃ§" adi altinda kitlesel Ã¼retim yapmak farkli bir sey.
      <cite>&mdash; ABD Federal DÃ¼zenleyici Ã‡erÃ§eve</cite>
    </blockquote>

    <h3>Patent Haritasi: Nerede, Ne Zaman Doluyor?</h3>

    <p>2026 itibariyla semaglutid patentleri bazi Ã¶nemli pazarlarda sona ermeye baÅŸlÄ±yor. Ancak bu her Ã¼lke iÃ§in ayni anlama gelmiyor.</p>

    <div class="bar-chart anim-slide-up">
      <h4>Semaglutid Patent Suresi Dolma Takvimi</h4>
      <div class="bar-row">
        <span class="bar-label">Cin, Hindistan</span>
        <div class="bar-track"><div class="bar-fill clr-accent" style="width:30%">2026</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Brezilya, Kanada</span>
        <div class="bar-track"><div class="bar-fill clr-primary" style="width:45%">2027-28</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Avrupa</span>
        <div class="bar-track"><div class="bar-fill clr-dark" style="width:70%">~2030</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">ABD</span>
        <div class="bar-track"><div class="bar-fill clr-success" style="width:90%">2032</div></div>
      </div>
    </div>

    <p>Bu tablo soyle okunmalÄ±: Cin ve Hindistan gibi yÃ¼ksek hacimli pazarlarda semaglutid jenerikleri 2026'dan itibaren yasal olarak uretilmeye baÅŸlayabilir. Ancak ABD ve Avrupa'da patent korumalari hala gÃ¼Ã§lÃ¼. Bu durum, Ã¶zellikle TÃ¼rkiye gibi Ã¼lkelerde jenerik eriÅŸimi iÃ§in Ã¶nemli bir referans noktasi oluÅŸturuyor.</p>

    <h2 id="bolum-3">FDA'nin Kopya GLP-1'lere Karsi Tutumu</h2>

    <p>ABD Gida ve Ä°laÃ§ Dairesi (FDA), Subat 2026'da onaysiz GLP-1 ilaÃ§lariyla ilgili kapsamli bir uyarÄ± yayÄ±mladÄ±. UyarÄ±da birden fazla gÃ¼venlik endisesi sÄ±ralanÄ±yordu.</p>

    <div class="blog-box warning anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M10.29 3.86L1.82 18a2 2 0 001.71 3h16.94a2 2 0 001.71-3L13.71 3.86a2 2 0 00-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>
      <div class="box-body">
        <strong>FDA UyarÄ±lari &mdash; Kopya GLP-1 Riskleri</strong>
        <ul>
          <li><strong>Dozaj hatalari:</strong> Hem hastalar hem klinisyenler tarafindan yapilan ciddi dozaj hatalari bildirildi</li>
          <li><strong>GÃ¼venlik dogrulanmamis:</strong> Kopya ilaÃ§larin gÃ¼venlilik, etkinlik ve kalitesi regÃ¼latÃ¶rler tarafindan doÄŸrulanmÄ±yor</li>
          <li><strong>Ciddi yan etkiler:</strong> Bazi agir advers olaylar raporlandi</li>
          <li><strong>Kitlesel Ã¼retim sorunu:</strong> "KiÅŸisellestirilmis" adi altinda kitlesel stok Ã¼retimi yasadÄ±ÅŸÄ±</li>
        </ul>
      </div>
    </div>

    <p>FDA'nin bu karari, kopya GLP-1 pazarindaki "Vahsi Bati" dÃ¶neminin sona erdiginin en gÃ¼Ã§lÃ¼ sinyali. Ä°laÃ§ kÄ±tlÄ±ÄŸi dÃ¶neminde goz yumulan kopya Ã¼retim, artik kÄ±tlÄ±k sona erdigi iÃ§in yasal dayanaklarini yitirmis durumda.</p>

    <h2 id="bolum-4">Yeni Nesil Ä°laÃ§lar: ÃœÃ§lÃ¼ Agonistler ve Oral Tedaviler</h2>

    <p>Patent savaÅŸlarÄ± surerken, bilim dunyasi bos durmuyor. GLP-1 sinifinin olgunlaÅŸmasi, yeni bir inovasyon dalgasini tetikledi. BCG Biopharma Trends 2026 raporuna gore, kilo yonetimi alaninda <strong>100'den fazla bileÅŸigin</strong> geliÅŸtirme aÅŸamasÄ±nda oldugu belirtiliyor.</p>

    <h3>Coklu Agonist Yaklasimi</h3>

    <p>Birinci nesil GLP-1'ler tek bir reseptoru hedefliyordu. Yeni nesil, birden fazla metabolik yolagi ayni anda aktive ediyor:</p>

    <table class="blog-table anim-slide-up">
      <thead>
        <tr><th>Ä°laÃ§/Molekul</th><th>Mekanizma</th><th>Hedef Reseptorler</th><th>Durum</th></tr>
      </thead>
      <tbody>
        <tr><td><strong>Tirzepatid</strong> (Mounjaro/Zepbound)</td><td>Ikili agonist</td><td>GLP-1 + GIP</td><td>Onaylanmis, piyasada</td></tr>
        <tr><td><strong>CagriSema</strong></td><td>Semaglutid + Amilin analoÄŸu</td><td>GLP-1 + Amilin</td><td>Faz 3 Ã§alÄ±ÅŸmalari</td></tr>
        <tr><td><strong>Retatrutid</strong></td><td>ÃœÃ§lÃ¼ agonist</td><td>GLP-1 + GIP + Glukagon</td><td>Faz 3 Ã§alÄ±ÅŸmalari</td></tr>
        <tr><td><strong>Orforglipron</strong></td><td>Oral kucuk molekÃ¼l</td><td>GLP-1</td><td>Faz 3 Ã§alÄ±ÅŸmalari</td></tr>
      </tbody>
    </table>

    <h3>Retatrutid: ÃœÃ§lÃ¼ Agonist Devrimi</h3>

    <p>Retatrutid, ÅŸu an klinik Ã§alÄ±ÅŸmalarda olan dikkat Ã§ekici molekÃ¼llerden biri. GLP-1, GIP ve glukagon reseptÃ¶rlerini aynÄ± anda aktive ederek daha geniÅŸ metabolik etkiler sunuyor. Faz 2 Ã§alÄ±ÅŸmasÄ±nda (Jastreboff et al., <em>NEJM</em> 2023; n=338) 12mg dozunda <strong>vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ±nÄ±n %24.2'sine varan kayÄ±plar</strong> gÃ¶zlemlendi ğŸŸ¡ (Faz 2, kÃ¼Ã§Ã¼k Ã¶rneklem â€” Faz 3 ile doÄŸrulanmasÄ± bekleniyor).</p>

    <div class="key-stat anim-slide-up">
      <span class="ks-num">%24</span>
      <span class="ks-text">Retatrutidin Faz 2 Ã§alÄ±ÅŸmasÄ±nda (12mg, 48 hafta) gÃ¶zlemlenen maksimum vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ± kaybÄ± oranÄ± ğŸŸ¡ (Faz 2, n=338 â€” Faz 3 sonuÃ§larÄ± bekleniyor).</span>
    </div>

    <h3>Orforglipron: Igneden Hapa Gecis</h3>

    <p>GLP-1 tedavilerinin en bÃ¼yÃ¼k engellerinden biri enjeksiyon gerekliligidir. Orforglipron, peptid olmayan oral bir GLP-1 reseptor agonisti olarak bu engeli asmayi hedefliyor. Klinik verilerde anlamli kilo kaybi gosterirken, gÃ¼venlik ve tolerabilite profili mevcut enjektabl tedavilerle karÅŸÄ±laÅŸtÄ±riabilir bulundu.</p>

    <div class="blog-box success anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M22 11.08V12a10 10 0 11-5.93-9.14"/><polyline points="22 4 12 14.01 9 11.01"/></svg>
      <div class="box-body">
        <strong>Oral GLP-1'lerin Avantajlari</strong>
        <ul>
          <li>Enjeksiyon korkusu olan hastalar iÃ§in eriÅŸilebilirlik</li>
          <li>Daha iyi tedavi uyumu (adherence)</li>
          <li>Daha dÃ¼ÅŸÃ¼k Ã¼retim maliyeti potansiyeli</li>
          <li>Daha uzun fonksiyonel yari omur</li>
        </ul>
      </div>
    </div>

    <p>Ancak Ã¶nemli bir soru var: Oral kucuk molekÃ¼l GLP-1 agonistleri, agir obezite hastalarinda enjektabl peptid ajanlarin kilo kaybi etkinligini yakalayabilir mi? Bu soru henuz kesin olarak cevaplanmadi.</p>

    <h2 id="bolum-5">KarÅŸÄ±laÅŸtÄ±rma: Mevcut ve Gelecek GLP-1 Tedavileri</h2>

    <figure class="blog-infographic anim-slide-up">
      <svg viewBox="0 0 700 320" xmlns="http://www.w3.org/2000/svg">
        <!-- Background -->
        <rect width="700" height="320" rx="16" fill="#f8fafc"/>
        <!-- Title -->
        <text x="350" y="35" text-anchor="middle" font-family="Inter,sans-serif" font-size="16" font-weight="700" fill="#0D7377">GLP-1 Tedavi Nesilleri: Kilo Kaybi KarÅŸÄ±laÅŸtÄ±rmasi</text>
        <!-- Bars -->
        <!-- Semaglutid -->
        <rect x="60" y="65" width="200" height="40" rx="6" fill="#14919B" opacity="0.85"/>
        <text x="65" y="90" font-family="Inter,sans-serif" font-size="13" font-weight="700" fill="white">Semaglutid (Wegovy)</text>
        <text x="270" y="90" font-family="Inter,sans-serif" font-size="13" font-weight="600" fill="#334155">~%15 kilo kaybi</text>
        <!-- Tirzepatid -->
        <rect x="60" y="120" width="300" height="40" rx="6" fill="#0D7377"/>
        <text x="65" y="145" font-family="Inter,sans-serif" font-size="13" font-weight="700" fill="white">Tirzepatid (Mounjaro)</text>
        <text x="370" y="145" font-family="Inter,sans-serif" font-size="13" font-weight="600" fill="#334155">~%20 kilo kaybi</text>
        <!-- CagriSema -->
        <rect x="60" y="175" width="340" height="40" rx="6" fill="#E8963E"/>
        <text x="65" y="200" font-family="Inter,sans-serif" font-size="13" font-weight="700" fill="white">CagriSema</text>
        <text x="410" y="200" font-family="Inter,sans-serif" font-size="13" font-weight="600" fill="#334155">~%22 kilo kaybi*</text>
        <!-- Retatrutid -->
        <rect x="60" y="230" width="400" height="40" rx="6" fill="#195157"/>
        <text x="65" y="255" font-family="Inter,sans-serif" font-size="13" font-weight="700" fill="white">Retatrutid (ÃœÃ§lÃ¼ Agonist)</text>
        <text x="470" y="255" font-family="Inter,sans-serif" font-size="13" font-weight="600" fill="#334155">~%24 kilo kaybi*</text>
        <!-- Footnote -->
        <text x="60" y="300" font-family="Inter,sans-serif" font-size="11" fill="#94a3b8">* Faz 2 verileri (nihai Faz 3 sonuÃ§larÄ± deÄŸiÅŸebilir). Kaynaklar: Jastreboff NEJM 2023, Novo Nordisk REDEFINE verileri</text>
      </svg>
      <figcaption>GLP-1 tedavi nesillerinin klinik Ã§alÄ±ÅŸmalarda gÃ¶sterdiÄŸi ortalama kilo kaybi oranlarÄ±</figcaption>
    </figure>

    <h2 id="bolum-6">TÃ¼rkiye Ä°Ã§in Ne Anlama Geliyor?</h2>

    <p>TÃ¼rkiye, Avrupa'nin en yÃ¼ksek obezite oranina sahip Ã¼lkelerinden biri. Bu global geliÅŸmeler Ã¼lkemiz iÃ§in birkac Ã¶nemli anlam taÅŸÄ±yor:</p>

    <div class="blog-box info anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="16" x2="12" y2="12"/><line x1="12" y1="8" x2="12.01" y2="8"/></svg>
      <div class="box-body">
        <strong>TÃ¼rkiye'ye Ã–zel Ã‡Ä±karÄ±mlari</strong>
        <ul>
          <li><strong>Jenerik eriÅŸim:</strong> Patent sÃ¼relerinin dolmasi, TÃ¼rkiye'de daha uygun fiyatli GLP-1 jeneriklerine kapÄ± acabilir &mdash; ancak EMA/Avrupa patent takvimi (~2030) belirleyici olacak</li>
          <li><strong>TITCK dÃ¼zenlemeleri:</strong> Kopya ilaÃ§ tartismalari, TÃ¼rkiye'de de onaysiz Ã¼rÃ¼nlere karsi farkindaligin artmasini saglayabilir</li>
          <li><strong>Yeni nesil ilaÃ§lar:</strong> Retatrutid ve orforglipron gibi molekÃ¼llerin TÃ¼rkiye'ye gelisi birkaÃ§ yil alabilir, ancak tedavi secenekleri geniÅŸleyecek</li>
          <li><strong>Oral tedaviler:</strong> Enjeksiyon korkusu TÃ¼rkiye'de de yaygin; oral GLP-1'ler tedavi uyumunu Ã¶nemli Ã¶lÃ§Ã¼de artÄ±rabilir</li>
        </ul>
      </div>
    </div>

    <div class="key-stat danger anim-slide-up">
      <span class="ks-num">~%32</span>
      <span class="ks-text">TÃ¼rkiye'de yetiÅŸkin obezite oranÄ± (OECD 2024, BMI â‰¥30). Bu oran, Ã¼lkemizi Avrupa'nÄ±n en yÃ¼ksek obezite oranlarÄ±na sahip Ã¼lkelerinden biri yapÄ±yor ve etkili tedavilere eriÅŸimi kritik hale getiriyor.</span>
    </div>

    <div class="blog-box tip anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M12 2L2 7l10 5 10-5-10-5z"/><path d="M2 17l10 5 10-5"/><path d="M2 12l10 5 10-5"/></svg>
      <div class="box-body">
        <strong>Ã–nemli HatÄ±rlatma</strong>
        <p>GLP-1 ilaÃ§lari reÃ§eteye tabi ilaÃ§lardir ve mutlaka bir hekim gÃ¶zetiminde kullanilmalidir. Internetten veya onaysiz kaynaklardan temin edilen kopya Ã¼rÃ¼nler ciddi saÄŸlÄ±k riskleri taÅŸÄ±r. Tedavi karari iÃ§in mutlaka doktorunuza danÄ±ÅŸÄ±n.</p>
      </div>
    </div>

    <h2 id="bolum-7">Sonuc ve Ana Ã‡Ä±karÄ±mlar</h2>

    <p>2026, GLP-1 ilaÃ§ sÄ±nÄ±fÄ± iÃ§in Ã¶nemli bir dÃ¶nÃ¼ÅŸÃ¼m yÄ±lÄ±. Patent savaÅŸlarÄ±, dÃ¼zenleyici deÄŸiÅŸiklikler ve yeni nesil molekÃ¼ller bir arada ilerlerken, obezite tedavi seÃ§enekleri geniÅŸlemeye devam ediyor â€” ancak doÄŸru ve gÃ¼venilir bilgiye dayalÄ± kararlar vermek her zamankinden Ã¶nemli.</p>

    <div class="blog-takeaway anim-slide-up">
      <h4>Ana Ã‡Ä±karÄ±mlar</h4>
      <ul>
        <li>Semaglutid patentleri bazi Ã¼lkelerde 2026'da doluyor, ancak ABD ve Avrupa'da koruma 2030-2032'ye kadar sÃ¼rÃ¼yor</li>
        <li>Novo Nordisk, kopya GLP-1 Ã¼retimini durdurmak iÃ§in agresif hukuki adimlar atÄ±yor</li>
        <li>FDA, onaysiz kopya GLP-1'lerin ciddi gÃ¼venlik riskleri tasÄ±digini uyardi</li>
        <li>Retatrutid (Ã¼Ã§lÃ¼ agonist) ve orforglipron (oral) gibi yeni nesil tedaviler, mevcut ilaÃ§lari aÅŸan sonuclar vaat ediyor</li>
        <li>100'den fazla yeni molekÃ¼l geliÅŸtirme aÅŸamasÄ±nda &mdash; tedavi secenekleri hÄ±zla geniÅŸliyecek</li>
        <li>TÃ¼rkiye iÃ§in jenerik eriÅŸim 2028-2030 arasi gerÃ§eklesebilir; bu sÃ¼reÃ§te doktor danÄ±ÅŸmanligiyla onaylanmis ilaÃ§lari tercih edin</li>
      </ul>
    </div>

  </div>

  <!-- Social Sharing -->
  <div class="blog-share">
    <span>Paylas:</span>
    <a class="share-btn" href="https://twitter.com/intent/tweet?url=https://uzunyasa.com/pages/blog/glp1-patent-savaÅŸlarÄ±-2026-yeni-nesil-ilaÃ§lar.html&text=GLP-1%20Patent%20SavaÅŸlarÄ±%20ve%20Yeni%20Nesil%20Ä°laÃ§lar%3A%202026%27da%20Neler%20DeÄŸiÅŸiyor%3F" target="_blank" rel="noopener" aria-label="Twitter'da paylas">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"/></svg>
    </a>
    <a class="share-btn" href="https://www.linkedin.com/sharing/share-offsite/?url=https://uzunyasa.com/pages/blog/glp1-patent-savaÅŸlarÄ±-2026-yeni-nesil-ilaÃ§lar.html" target="_blank" rel="noopener" aria-label="LinkedIn'de paylas">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433a2.062 2.062 0 01-2.063-2.065 2.064 2.064 0 112.063 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"/></svg>
    </a>
    <a class="share-btn" href="https://wa.me/?text=GLP-1%20Patent%20SavaÅŸlarÄ±%20ve%20Yeni%20Nesil%20Ä°laÃ§lar%20https://uzunyasa.com/pages/blog/glp1-patent-savaÅŸlarÄ±-2026-yeni-nesil-ilaÃ§lar.html" target="_blank" rel="noopener" aria-label="WhatsApp'ta paylas">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M17.472 14.382c-.297-.149-1.758-.867-2.03-.967-.273-.099-.471-.148-.67.15-.197.297-.767.966-.94 1.164-.173.199-.347.223-.644.075-.297-.15-1.255-.463-2.39-1.475-.883-.788-1.48-1.761-1.653-2.059-.173-.297-.018-.458.13-.606.134-.133.298-.347.446-.52.149-.174.198-.298.298-.497.099-.198.05-.371-.025-.52-.075-.149-.669-1.612-.916-2.207-.242-.579-.487-.5-.669-.51-.173-.008-.371-.01-.57-.01-.198 0-.52.074-.792.372-.272.297-1.04 1.016-1.04 2.479 0 1.462 1.065 2.875 1.213 3.074.149.198 2.096 3.2 5.077 4.487.709.306 1.262.489 1.694.625.712.227 1.36.195 1.871.118.571-.085 1.758-.719 2.006-1.413.248-.694.248-1.289.173-1.413-.074-.124-.272-.198-.57-.347m-5.421 7.403h-.004a9.87 9.87 0 01-5.031-1.378l-.361-.214-3.741.982.998-3.648-.235-.374a9.86 9.86 0 01-1.51-5.26c.001-5.45 4.436-9.884 9.888-9.884 2.64 0 5.122 1.03 6.988 2.898a9.825 9.825 0 012.893 6.994c-.003 5.45-4.437 9.884-9.885 9.884m8.413-18.297A11.815 11.815 0 0012.05 0C5.495 0 .16 5.335.157 11.892c0 2.096.547 4.142 1.588 5.945L.057 24l6.305-1.654a11.882 11.882 0 005.683 1.448h.005c6.554 0 11.89-5.335 11.893-11.893a11.821 11.821 0 00-3.48-8.413z"/></svg>
    </a>
  </div>

  <!-- Author Box -->
  <div class="blog-author anim-slide-up">
    <div class="blog-author-avatar">UY</div>
    <div class="blog-author-info">
      <h4>UzunYasa EditÃ¶ryal Ekibi</h4>
      <p>TÄ±bbi Inceleme: Endokrinoloji ve Ic Hastaliklari Uzmanlari DanÄ±ÅŸma Kurulu</p>
    </div>
  </div>

  <!-- CTA -->
  <div class="blog-cta anim-slide-up">
    <h3>Kilo yonetimi yolculugunuza baÅŸlayÄ±n</h3>
    <p>KiÅŸisellestirilmis degerlendirme iÃ§in Ã¼cretsiz testimizi tamamlayin</p>
    <a href="../test.html">Teste BaÅŸla &rarr;</a>
  </div>

  <!-- Related Posts -->
  <div class="blog-related anim-slide-up">
    <h3>Ilgili Yazilar</h3>
    <div class="related-grid">
      <a href="glp1-tam-rehber.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>GLP-1 Tam Rehber: Bilmeniz Gereken Her Sey</h4>
          <p>15 dk okuma</p>
        </div>
      </a>
      <a href="oral-glp1-orforglipron-igneden-hapa.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1585435557343-3b092031a831?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>Oral GLP-1: Igneden Hapa Gecis</h4>
          <p>10 dk okuma</p>
        </div>
      </a>
      <a href="fda-kopya-glp1-yasaklari-v2.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1532938911079-1b06ac7ceec7?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>FDA Kopya GLP-1 Yasaklari</h4>
          <p>8 dk okuma</p>
        </div>
      </a>
    </div>
  </div>

  <!-- Newsletter -->
  <div class="blog-newsletter anim-slide-up">
    <h3>SaÄŸlÄ±k Bultenimize Katilin</h3>
    <p>Haftanin en Ã¶nemli saÄŸlÄ±k haberleri ve bilimsel geliÅŸmeleri e-postaniza gelsin.</p>
    <form class="newsletter-form" onsubmit="return false;">
      <input type="email" placeholder="E-posta adresiniz" required>
      <button type="submit">Abone Ol</button>
    </form>
  </div>

  <!-- Disclaimer -->
  <div class="blog-disclaimer">
    <strong>Yasal UyarÄ±:</strong> Bu yazi bilgilendirme amaÃ§lidir ve tÄ±bbi tavsiye niteligi taÅŸÄ±maz.
    Tedavi kararlari iÃ§in mutlaka bir saÄŸlÄ±k profesyoneline danÄ±ÅŸÄ±n.
    <br><br>
    <strong>Kaynaklar:</strong><br>
    1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity â€” a phase 2 trial. <em>N Engl J Med.</em> 2023;389(6):514-526.<br>
    2. Novo Nordisk. CagriSema (semaglutide + cagrilintide) REDEFINE Phase 3 program. ClinicalTrials.gov.<br>
    3. CNBC. "Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs." 9 Åubat 2026 (haber kaynaÄŸÄ±).<br>
    4. FDA. Drug Safety Communication â€” Compounded GLP-1 Products. Åubat 2026.<br>
    5. Medscape. "FDA Lists Multiple Concerns About Unapproved GLP-1 Drugs." Åubat 2026 (haber kaynaÄŸÄ±).<br>
    6. Precedence Research. "Obesity GLP-1 Market Size to Hit USD 66.57 Billion by 2035." 2026 (pazar araÅŸtÄ±rmasÄ±).<br>
    7. BCG Biopharma Trends 2026 Report (sektÃ¶r raporu).<br>
    8. OECD Health Statistics. Obesity Update â€” Turkey country note, 2024.
  </div>

</article>

<!-- FOOTER -->
<footer class="footer">
  <div class="footer-inner">
    <div class="footer-grid">
      <div class="footer-brand">
        <img src="/images/logo-new.png" alt="UzunYasa" class="footer-logo">
        <p>TÃ¼rkiye uzun yaÅŸasÄ±n diye. Kanita dayali saÄŸlÄ±k bilgisi ve araclari.</p>
      </div>
      <div class="footer-col">
        <h4>Kesfet</h4>
        <a href="../beslenme.html">Beslenme</a>
        <a href="../egzersiz.html">Egzersiz</a>
        <a href="../tedavi.html">Kilo Yonetimi</a>
        <a href="../uyku-stres.html">Zihin & Davranis</a>
      </div>
      <div class="footer-col">
        <h4>Araclar</h4>
        <a href="../araclar.html">Tum Araclar</a>
        <a href="../test.html">KiÅŸisel Test</a>
        <a href="../blog.html">Blog</a>
      </div>
      <div class="footer-col">
        <h4>Hakkimizda</h4>
        <a href="../hakkimizda.html">Ekibimiz</a>
        <a href="../bilim.html">Bilim</a>
        <a href="https://tyzd.org" target="_blank">TYZD</a>
      </div>
    </div>
    <div class="footer-bottom">
      <span>&copy; 2026 UzunYasa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">Tipta Yapay Zeka Dernegi</a> girisimidir.</span>
      <span style="font-size:0.8rem;opacity:0.5;">Bu site tÄ±bbi tavsiye sunmaz. Tedavi iÃ§in doktorunuza danÄ±ÅŸÄ±n.</span>
    </div>
  </div>
</footer>

<!-- Scripts -->
<script>
// Reading Progress Bar
window.addEventListener('scroll', () => {
  const article = document.querySelector('.blog-article');
  if (!article) return;
  const rect = article.getBoundingClientRect();
  const total = article.scrollHeight - window.innerHeight;
  const scrolled = -rect.top;
  const pct = Math.min(Math.max(scrolled / total * 100, 0), 100);
  document.getElementById('blogProgress').style.width = pct + '%';
});

// Scroll Animation Observer
const observer = new IntersectionObserver((entries) => {
  entries.forEach(e => {
    if (e.isIntersecting) {
      e.target.classList.add('anim-visible');
      observer.unobserve(e.target);
    }
  });
}, { threshold: 0.15 });

document.querySelectorAll('.anim-slide-up, .bar-fill').forEach(el => {
  if (!el.classList.contains('anim-visible')) observer.observe(el);
});

// Header scroll effect
window.addEventListener('scroll', () => {
  const header = document.querySelector('.header');
  if (window.scrollY > 60) {
    header.classList.add('scrolled');
  } else {
    header.classList.remove('scrolled');
  }
});
</script>
<script src="../../scripts/animations.js"></script>
</body>
</html>